- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01634516
Effectiveness of Mediterranean Diet Intervention in Pregnant Women
An Investigation of the Effectiveness of the Mediterranean Diet in Pregnant Women at Risk of Developing Allergy in Their Infants: Pilot Randomised Controlled Trial
There has been an increase in asthma and allergic disease prevalence, especially in children. Given the high prevalence, and the associated high disease burden and costs, there is an urgent need to identify effective strategies for the primary prevention of asthma and allergy. A systematic review of the literature has found strong supportive epidemiological evidence of a protective role for the Mediterranean Diet (MD).
The investigators aim is to undertake a pilot trial in a sample of pregnant women to establish recruitment, retention, a measurable change to a dietary intervention encouraging greater adherence to a MD during pregnancy, and acceptability of the dietary advice and diet modifications.
This pilot study will be a 2-arm randomised controlled trial (RCT) in a sample population of around 50 Scottish pregnant women.
This work ultimately aims to contribute to improving health outcomes through seeking to reduce the incidence of asthma and allergic problems. This pilot trial will prove invaluable in informing the subsequent planned definitive parallel group RCT.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Aims
The primary aims of this pilot trial are to investigate rates of maternal recruitment and retention, and adherence with a MD during the latter two trimesters of pregnancy (i.e. weeks 12 to 36). The secondary aims are to determine whether there is any subsequent measurable change in the Mediterranean Diet score and whether the dietary advice and diet modifications are acceptable.
Research questions
- What are the recruitment and retention rates of pregnant mothers whose infants are at high risk of atopic disease?
- Is the advice and dietary modification acceptable to participants?
- To what extent are mothers able to adhere to a MD?
- Can a MD score be increased in pregnancy?
- Can a measurable change in a biomarker of oxidative stress be detected as a result of adherence to a MD?
- Can any increases in MD be sustained during pregnancy?
Design
- Trial design This is a two-arm pilot RCT. Trial participants will be recruited from 2-3 hospitals/community treatment centres in Scotland.
Participant recruitment
Pregnant women aged 16 years and above will be sent a letter of invitation, information for participants, and a consent form for the trial with their dating scan appointment by the hospital. Interested participants will be invited to contact the researcher by text, phone or email to discuss the project and answer any questions they may have; they will then be screened for eligibility to take part in the trial.
Eligibility of high risk women is defined as: those with one or more first degree blood relatives with atopic dermatitis (eczema), a food allergy, allergic rhinitis (hay fever) or asthma, using the question 'Do you, the mother, or the father or sibling of the baby have an allergic disease: eczema, a food allergy, hay fever or asthma?' Responses will be recorded on the screening questionnaire.
The researcher will send to the participant a food frequency questionnaire for completion at home and a urine container with instructions to fill the container on the day of the scan and bring it, with the Consent form and the completed FFQ along with them to hand over to the researcher. The urine specimen will be used for the analysis of markers of oxidative stress, antioxidant activity and nitric oxide (NO) synthesis. The researcher will greet the participant in the waiting area of the clinic prior to their dating scan where their consent form, urine sample and FFQ will be collected. After their scan, consenting eligible participants will complete a baseline MD questionnaire.
Intervention
The intervention is a 15 minute dietary advice session directed at increasing the MD score, with subsequent telephone support sessions throughout the pregnancy.
Intervention arm
Mothers randomised to the intervention arm will meet with the project researcher when visiting the hospital for their first dating scan. After the scan, participants will receive a 15 minute dietary advice session, encouraging the consumption of particular foods that are consistent with the MD, and the key messages will be supplemented through written/visual materials, and through regular supportive telephone calls. No energy restrictions will be suggested. A £10 supermarket voucher will be given to the participants.
The first follow-up by the researcher will be by telephone 12 weeks post-baseline MD questionnaire to inform them they will receive the second MD questionnaire and reply envelope for completion and return. A further supermarket voucher to the value of £10 will be sent to the participant on receipt of the completed form.
Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher will contact participants by phone and arrange a home visit. When visited at home by the researcher, a third MD questionnaire and second FFQ will be completed and handed to the researcher and a urine sample will be obtained.
Free and continuous telephone access to the researcher will be available throughout the study.
Control arm
Mothers randomised to the control arm will meet with the project researcher when visiting the hospital for their first dating scan. The participant will not receive the 15 minute dietary advice session. A £10 supermarket voucher will be given to the participants. The first follow-up by the researcher will be by telephone 12 weeks post-baseline MD questionnaire to inform them they will receive the second MD questionnaire and reply envelope for completion and return. A further supermarket voucher to the value of £10 will be sent to the participant on receipt of the completed form.
Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher will contact participants by phone and arrange a home visit. When visited at home by the researcher, a third MD questionnaire and second FFQ will be completed and handed to the researcher and a urine sample will be obtained.
Randomisation
Allocation to the intervention or control arm will be via pre-randomised sealed envelopes, based on a predetermined random number allocation, restricted by recruitment site. This restricted randomisation will be carried out by an independent statistician.
- Follow-up Participants will be enrolled for a total of ~7 months (i.e. from 12-36 weeks of pregnancy).
Outcome measures
- Recruitment rate (i.e. the proportion of those invited to take part compared with the number of consenting women)
- Retention rate (i.e. the proportion of those starting the study to those finishing)
- Change in MD score from baseline to 24 and 36 weeks of pregnancy
- Change in oxidative stress and whole-body NO production
- Acceptability of dietary advice and diet modifications
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Scotland
-
Edinburgh, Scotland, Verenigd Koninkrijk
- Leith Community Treatment Centre
-
Livingston, Scotland, Verenigd Koninkrijk, EH54 6PP
- St John's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Pregnant in first trimester
- Age 16 years and above
- One or more first degree blood relatives of the baby with atopic dermatitis(eczema), food allergy, allergic rhinitis (persistent or intermittent) or asthma
- Willing to give informed consent
Exclusion Criteria:
- Age <16 years
- No first degree blood relatives of the baby with atopic dermatitis (eczema), food allergy, allergic rhinitis (persistent or intermittent) or asthma
- Recent (within the last 3 months) or current involvement in a dietary or supplementation trial
- Unable to give informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dietary support
Face to face intervention plus subsequent telephone support
|
Face to face intervention plus subsequent telephone support
|
|
Placebo-vergelijker: No dietary support
No face to face intervention plus subsequent telephone support
|
No face to face intervention or subsequent telephone support
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Recruitment rate of pregnant mothers whose infants are at high risk of atopic disease.
Tijdsspanne: 4 months
|
4 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Mediterranean Diet score in pregnancy
Tijdsspanne: 12 and 24 weeks post-intervention
|
12 and 24 weeks post-intervention
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Dean A. Sewell, PhD, Heriot-Watt University
- Studie stoel: Aziz Sheikh, MBBS, MD, University of Edinburgh
Publicaties en nuttige links
Algemene publicaties
- Sewell DA, Hammersley VS, Devereux G, Robertson A, Stoddart A, Weir C, Worth A, Sheikh A. Investigating the effectiveness of the Mediterranean diet in pregnant women for the primary prevention of asthma and allergy in high-risk infants: protocol for a pilot randomised controlled trial. Trials. 2013 Jun 14;14:173. doi: 10.1186/1745-6215-14-173.
- Sewell DA, Hammersley VS, Robertson A, Devereux G, Stoddart A, Weir CJ, Worth A, Sheikh A. A pilot randomised controlled trial investigating a Mediterranean diet intervention in pregnant women for the primary prevention of allergic diseases in infants. J Hum Nutr Diet. 2017 Oct;30(5):604-614. doi: 10.1111/jhn.12469. Epub 2017 Feb 16.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HWU113821/UoE
- CZG/2/558 (Ander subsidie-/financieringsnummer: CSO)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Dietary support
-
University of PrimorskaCommunity Healthcare Center dr. Adolf Drolc Maribor (HCM)Actief, niet wervend
-
Universidade do PortoWervingPostpartum | Cardiometabolische factoren | Cardiale omgekeerde remodelleringPortugal
-
Unity Health TorontoCanadian Diabetes AssociationVoltooidCoronaire hartziekte | Diabetes mellitus type IICanada
-
Oregon Health and Science UniversityVoltooidOngerustheid | Impulsiviteit | OnoplettendheidVerenigde Staten
-
Johns Hopkins UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Nog niet aan het wervenLotgenotenondersteuning voor Levertransplantatiepatiënten met een Voorgeschiedenis van ALD (THRIVES)Alcoholgebruiksstoornis | Ontvanger van levertransplantatie | Alcoholgerelateerde leverziekteVerenigde Staten
-
Denver Health and Hospital AuthorityNational Heart, Lung, and Blood Institute (NHLBI)VoltooidTracheostomie | Acuut ademhalingsfalen | Mechanische ventilatieVerenigde Staten
-
Istanbul Aydın UniversityIstanbul University - CerrahpasaVoltooidAutisme Spectrum StoornisTurkije (Türkiye)
-
Brigham and Women's HospitalAmgenBeëindigdReumatoïde artritisVerenigde Staten
-
Children's Mercy Hospital Kansas CityVoltooidDiabetes type 1Verenigde Staten
-
Harvard UniversityBeëindigdZelfmoord | Nood, emotioneelVerenigde Staten